Medifast (MED) Tops Q1 EPS by 41c; Guides Q2 Lower

Medifast (NYSE: MED) reported Q1 EPS of $3.67, $0.41 better than the analyst estimate of $3.26. Revenue for the quarter came in at $349 million versus the consensus estimate of $374.3 million.

GUIDANCE:

Medifast sees Q2 2023 EPS of $1.32-$1.44, versus the consensus of $2.82. Medifast sees Q2 2023 revenue of $250-270 million, versus the consensus of $313.16 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI